Research, development and out-licensing of diagnostic and therapeutic antibodies for GIST
First written in FY2021. 2 of 3 entries say "Advanced", first in FY2023. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AdvancedAnnual report
「We have obtained a patent in Japan for an “antibody fragment specific to c-KIT-positive tumour”; see the “Notice of Patent Grant” published on 4 April 2024. We are currently discussing future plans with potential partners.」
The GIST diagnostic and therapeutic antibody has received a Japanese patent, and the programme has advanced to the discussion stage with potential partners. - FY2023AdvancedAnnual report
「We have completed the patent application and are now proceeding with preparations for preclinical studies.」
The patent application for the GIST diagnostic and therapeutic antibody has been completed, and the programme has advanced to the preparation stage for preclinical studies. - FY2021First statedAnnual report
「Together with Tokushima University, we will research and develop antibody drugs for the diagnosis and treatment of GIST (gastrointestinal stromal tumour), a type of sarcoma thought to arise from immature mesenchymal cells located beneath the mucosa of the stomach and intestinal walls, with the aim of out-licensing them to pharmaceutical companies and others.」
A theme aimed at researching and developing antibody drugs for the diagnosis and treatment of GIST through joint research with Tokushima University, and out-licensing them to pharmaceutical companies and others, was described for the first time.